Resumo
Diagnósticos diferenciais
Colaboradores
Autores
Dr George Tsaknis, MD, PhD, FRCP(London), MRQA, MAcadMEd, PGCert
Honorary Senior Lecturer
Department of Respiratory Sciences
University of Leicester
Leicester
UK
Consultant in Respiratory Medicine and Lung Cancer Lead
Clinical Director
Lung Cancer Screening Programme
Kettering General Hospital
Kettering
UK
Declarações
GT declares that he has no competing interests.
Dr Syed Hasan Mustafa Rizvi, MBBS, MRCP(London), AFHEA, PG. Dip Resp (Wales)
Lung Cancer Fellow
Respiratory Medicine
Kettering General Hospital
Kettering
UK
Declarações
SR declares that he has a stocks and shares ISA.
Agradecimentos
Dr George Tsaknis and and Dr Rizvi would like to gratefully acknowledge Dr Harvinder Virk, Dr Peter J. Mazzone and Dr Erik E. Folch MD, previous contributors to this topic.
Declarações
HV declares that he has no competing interests. PJM has been paid to participate in clinical advisory board meetings for Oncimmune, InDi, Nucleix, Grail, and Oncocyte, all companies interested in developing molecular biomarkers for the evaluation of lung nodules/lung cancer; he does not have a contractual agreement to disseminate product information for any of these companies. PJM has participated in research supported by InDi Veracyte, funding for which was paid to his institution. He has also participated in research with in-kind support from Oncimmune and 20/20 Genesystems. EEF is the global principal investigator for the NAVIGATE trial, sponsored by Medtronic. He has also served as scientific consultant for Boston Scientific in the development of advanced bronchoscopic techniques.
Revisores
Pallav L. Shah, MD, MBBS, FRCP
Consultant Physician
Royal Brompton Hospital
Chelsea & Westminster Hospital
London
UK
Declarações
PLS declares that he has no competing interests.
Roger Y. Kim, MD, MSCE, DAABIP
Assistant Professor of Medicine
Section of Interventional Pulmonology, Division of Pulmonary, Allergy, and Critical Care
University of Pennsylvania
Philadelphia
PA
Declarações
RYK currently receives grant funding from the National Cancer Institute of the National Institutes of Health, the American Cancer Society, the Respiratory Health Association, and the University of Pennsylvania McCabe Fund.
Créditos aos pareceristas
Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.
Declarações
As afiliações e declarações dos pareceristas referem--se ao momento da revisão.
Referências
Principais artigos
Callister ME, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015 Aug;70 Suppl 2:ii1-54.Texto completo
American College of Radiology. ACR appropriateness criteria: incidentally detected indeterminate pulmonary nodule. 2023 [internet publication].Texto completo
Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e93S-120.Texto completo Resumo
MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017 Jul;284(1):228-43.Texto completo Resumo
Ruparel M, Quaife SL, Navani N, et al. Pulmonary nodules and CT screening: the past, present and future. Thorax. 2016 Apr;71(4):367-75.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível aqui.
O uso deste conteúdo está sujeito ao nosso aviso legal
